At the experimental endpoint (either maximum tumor burden of 1.25 cm3 or 100 days post-transplantation), tumors/tissues at the site of transplantation were dissected and analyzed by flow cytometry for the human-specific antigen CD298 expression (Fig. 4B). This evidence concerns the gene ATP1B3 and neoplasm.